ARDELYX, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $0.00.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $742.00K, a 26.90% decline year-over-year.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $703.00K, a 40.87% decline year-over-year.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.72M, a 22.86% decline from fiscal 2024.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $2.23M, a 175.62% increase from fiscal 2023.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $808.00K, a 314.36% increase from fiscal 2022.
- ARDELYX, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $195.00K, a 76.19% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $742.00K 10-Q · filed 2026-04-30 | $1.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.72M 10-K · filed 2026-02-19 |
| 2025-09-30 | $703.00K 10-Q · filed 2025-10-30 | $1.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.01M 10-Q · filed 2026-04-30 | $2.20M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.23M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.19M 10-Q · filed 2025-10-30 | $2.23M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $1.71M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $1.04M 10-Q · filed 2025-05-01 | $1.71M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $808.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $670.00K 10-Q · filed 2024-10-31 | $808.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $250.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $138.00K 10-Q · filed 2024-05-02 | $250.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $195.00K 10-K · filed 2025-02-20 |
| 2022-09-30 | $112.00K 10-Q · filed 2023-10-31 | $195.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $424.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $83.00K 10-Q · filed 2023-05-03 | $424.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $819.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $341.00K 10-Q · filed 2022-11-03 | $819.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $937.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $478.00K 10-Q · filed 2022-05-05 | $937.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $834.00K 10-K · filed 2023-03-02 |
| 2020-09-30 | $459.00K 10-Q · filed 2021-11-12 | $833.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $574.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $375.00K 10-Q · filed 2021-05-06 | $574.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $396.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $200.00K 10-Q · filed 2020-11-05 | $397.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $390.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $198.00K 10-Q · filed 2020-05-07 | $390.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $491.00K 10-K · filed 2021-03-08 |
| 2018-09-30 | $193.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | |
| 2018-03-31 | $301.00K 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $62.00K 10-K · filed 2020-03-06 | |
| 2016-12-31 | $576.00K 10-K · filed 2019-03-06 | |
| 2015-12-31 | $548.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |